Methylation analyses in liquid biopsy

Translational Lung Cancer Research

Volumn 5, Issue 5, 2016, Pages 492-504

  Lissa, Delphine ^a   Robles, Ana I ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Biomarker; Bisulfitebased PCR assays; Cancer monitoring; Circulating tumor DNA (ctDNA); Early detection; Prognosis

Indexed keywords

BIOLOGICAL MARKER; CIRCULATING TUMOR DNA; DNA; UNCLASSIFIED DRUG;

CANCER PROGNOSIS; DNA DETERMINATION; DNA METHYLATION; EARLY DIAGNOSIS; FOLLOW UP; GENE MUTATION; GENE TRANSLOCATION; GENOMICS; HUMAN; LIQUID BIOPSY; LUNG BIOPSY; LUNG CANCER; MOLECULARLY TARGETED THERAPY; PRIMARY TUMOR; REVIEW; TREATMENT RESPONSE;

EID: 84995592140     PISSN: 22186751     EISSN: 22264477     Source Type: Journal    
DOI: 10.21037/tlcr.2016.10.03     Document Type: Review

References (91)

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin 2015;65:5-29.
2. National Lung Screening Trial Research Team, Aberle DR, Adams AM, et al. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med 2011;365:395-409.
3. Patz EF Jr, Pinsky P, Gatsonis C, et al. Overdiagnosis in low-dose computed tomography screening for lung cancer. JAMA Intern Med 2014;174:269-74.
4. Katki HA, Kovalchik SA, Berg CD, et al. Development and Validation of Risk Models to Select Ever-Smokers for CT Lung Cancer Screening. JAMA 2016;315:2300-11.
5. Aerts HJ, Velazquez ER, Leijenaar RT, et al. Decoding tumour phenotype by noninvasive imaging using a quantitative radiomics approach. Nat Commun 2014;5:4006.
6. Wang H, Schabath MB, Liu Y, et al. Semiquantitative Computed Tomography Characteristics for Lung Adenocarcinoma and Their Association With Lung Cancer Survival. Clin Lung Cancer 2015;16:e141-63.
7. Maldonado F, Duan F, Raghunath SM, et al. Noninvasive Computed Tomography-based Risk Stratification of Lung Adenocarcinomas in the National Lung Screening Trial. Am J Respir Crit Care Med 2015;192:737-44.
8. Chansky K, Sculier JP, Crowley JJ, et al. The International Association for the Study of Lung Cancer Staging Project: prognostic factors and pathologic TNM stage in surgically managed non-small cell lung cancer. J Thorac Oncol 2009;4:792-801.
9. Sharma S, Kelly TK, Jones PA. Epigenetics in cancer. Carcinogenesis 2010;31:27-36.
10. Cedar H, Bergman Y. Linking DNA methylation and histone modification: patterns and paradigms. Nat Rev Genet 2009;10:295-304.
11. Baylin SB. The cancer epigenome: its origins, contributions to tumorigenesis, and translational implications. Proc Am Thorac Soc 2012;9:64-5.
12. Baylin SB, Jones PA. Epigenetic Determinants of Cancer. Cold Spring Harb Perspect Biol 2016;8. pii: a019505.
13. Bird A. DNA methylation patterns and epigenetic memory. Genes Dev 2002;16:6-21.
14. Jones PA. The DNA methylation paradox. Trends Genet 1999;15:34-7.
15. Laurent L, Wong E, Li G, et al. Dynamic changes in the human methylome during differentiation. Genome Res 2010;20:320-31.
16. Jones PA. Functions of DNA methylation: islands, start sites, gene bodies and beyond. Nat Rev Genet 2012;13:484-92.
17. Liu F, Killian JK, Yang M, et al. Epigenomic alterations and gene expression profiles in respiratory epithelia exposed to cigarette smoke condensate. Oncogene 2010;29:3650-64.
18. Baylin SB, Jones PA. A decade of exploring the cancer epigenome-biological and translational implications. Nat Rev Cancer 2011;11:726-34.
19. Easwaran H, Johnstone SE, Van Neste L, et al. A DNA hypermethylation module for the stem/progenitor cell signature of cancer. Genome Res 2012;22:837-49.
20. Ohm JE, McGarvey KM, Yu X, et al. A stem cell-like chromatin pattern may predispose tumor suppressor genes to DNA hypermethylation and heritable silencing. Nat Genet 2007;39:237-42.
21. Schlesinger Y, Straussman R, Keshet I, et al. Polycombmediated methylation on Lys27 of histone H3 pre-marks genes for de novo methylation in cancer. Nat Genet 2007;39:232-6.
22. Rideout WM 3rd, Coetzee GA, Olumi AF, et al. 5-Methylcytosine as an endogenous mutagen in the human LDL receptor and p53 genes. Science 1990;249:1288-90.
23. Sato T, Arai E, Kohno T, et al. Epigenetic clustering of lung adenocarcinomas based on DNA methylation profiles in adjacent lung tissue: Its correlation with smoking history and chronic obstructive pulmonary disease. Int J Cancer 2014;135:319-34.
24. Hawes SE, Stern JE, Feng Q, et al. DNA hypermethylation of tumors from non-small cell lung cancer (NSCLC) patients is associated with gender and histologic type. Lung Cancer 2010;69:172-9.
25. Carvalho RH, Hou J, Haberle V, et al. Genomewide DNA methylation analysis identifies novel methylated genes in non-small-cell lung carcinomas. J Thorac Oncol 2013;8:562-73.
26. Selamat SA, Galler JS, Joshi AD, et al. DNA methylation changes in atypical adenomatous hyperplasia, adenocarcinoma in situ, and lung adenocarcinoma. PLoS One 2011;6:e21443.
27. Walter K, Holcomb T, Januario T, et al. DNA methylation profiling defines clinically relevant biological subsets of non-small cell lung cancer. Clin Cancer Res 2012;18:2360-73.
28. Shinjo K, Okamoto Y, An B, et al. Integrated analysis of genetic and epigenetic alterations reveals CpG island methylator phenotype associated with distinct clinical characters of lung adenocarcinoma. Carcinogenesis 2012;33:1277-85.
29. Cancer Genome Atlas Research Network. Comprehensive molecular profiling of lung adenocarcinoma. Nature 2014;511:543-50.
30. Brock MV, Hooker CM, Ota-Machida E, et al. DNA methylation markers and early recurrence in stage I lung cancer. N Engl J Med 2008;358:1118-28.
31. Sato T, Arai E, Kohno T, et al. DNA methylation profiles at precancerous stages associated with recurrence of lung adenocarcinoma. PLoS One 2013;8:e59444.
32. Sandoval J, Mendez-Gonzalez J, Nadal E, et al. A prognostic DNA methylation signature for stage I nonsmall-cell lung cancer. J Clin Oncol 2013;31:4140-7.
33. Robles AI, Arai E, Mathé EA, et al. An Integrated Prognostic Classifier for Stage I Lung Adenocarcinoma Based on mRNA, microRNA, and DNA Methylation Biomarkers. J Thorac Oncol 2015;10:1037-48.
34. Lui YY, Chik KW, Chiu RW, et al. Predominant hematopoietic origin of cell-free DNA in plasma and serum after sex-mismatched bone marrow transplantation. Clin Chem 2002;48:421-7.
35. El Messaoudi S, Rolet F, Mouliere F, et al. Circulating cell free DNA: Preanalytical considerations. Clin Chim Acta 2013;424:222-30.
36. Warton K, Lin V, Navin T, et al. Methylation-capture and Next-Generation Sequencing of free circulating DNA from human plasma. BMC Genomics 2014;15:476.
37. Diehl F, Schmidt K, Choti MA, et al. Circulating mutant DNA to assess tumor dynamics. Nat Med 2008;14:985-90.
38. Jahr S, Hentze H, Englisch S, et al. DNA fragments in the blood plasma of cancer patients: quantitations and evidence for their origin from apoptotic and necrotic cells. Cancer Res 2001;61:1659-65.
39. Fleischhacker M, Schmidt B. Circulating nucleic acids (CNAs) and cancer-a survey. Biochim Biophys Acta 2007;1775:181-232.
40. Schwarzenbach H, Alix-Panabières C, Müller I, et al. Cell-free tumor DNA in blood plasma as a marker for circulating tumor cells in prostate cancer. Clin Cancer Res 2009;15:1032-8.
41. Shaw JA, Brown J, Coombes RC, et al. Circulating tumor cells and plasma DNA analysis in patients with indeterminate early or metastatic breast cancer. Biomark Med 2011;5:87-91.
42. Thakur BK, Zhang H, Becker A, et al. Double-stranded DNA in exosomes: a novel biomarker in cancer detection. Cell Res 2014;24:766-9.
43. Balgkouranidou I, Chimonidou M, Milaki G, et al. SOX17 promoter methylation in plasma circulating tumor DNA of patients with non-small cell lung cancer. Clin Chem Lab Med 2016;54:1385-93.
44. Konecny M, Markus J, Waczulikova I, et al. The value of SHOX2 methylation test in peripheral blood samples used for the differential diagnosis of lung cancer and other lung disorders. Neoplasma 2016;63:246-53.
45. Zhang Y, Wang R, Song H, et al. Methylation of multiple genes as a candidate biomarker in non-small cell lung cancer. Cancer Lett 2011;303:21-8.
46. Kneip C, Schmidt B, Seegebarth A, et al. SHOX2 DNA methylation is a biomarker for the diagnosis of lung cancer in plasma. J Thorac Oncol 2011;6:1632-8.
47. Powrózek T, Krawczyk P, Nicos M, et al. Methylation of the DCLK1 promoter region in circulating free DNA and its prognostic value in lung cancer patients. Clin Transl Oncol 2016;18:398-404.
48. Powrózek T, Krawczyk P, Kucharczyk T, et al. Septin 9 promoter region methylation in free circulating DNApotential role in noninvasive diagnosis of lung cancer: preliminary report. Med Oncol 2014;31:917.
49. Ponomaryova AA, Rykova EY, Cherdyntseva NV, et al. Potentialities of aberrantly methylated circulating DNA for diagnostics and post-treatment follow-up of lung cancer patients. Lung Cancer 2013;81:397-403.
50. Balgkouranidou I, Chimonidou M, Milaki G, et al. Breast cancer metastasis suppressor-1 promoter methylation in cell-free DNA provides prognostic information in nonsmall cell lung cancer. Br J Cancer 2014;110:2054-62.
51. Ramirez JL, Rosell R, Taron M, et al. 14-3-3sigma methylation in pretreatment serum circulating DNA of cisplatin-plus-gemcitabine-treated advanced non-smallcell lung cancer patients predicts survival: The Spanish Lung Cancer Group. J Clin Oncol 2005;23:9105-12.
52. Wang H, Zhang B, Chen D, et al. Real-time monitoring efficiency and toxicity of chemotherapy in patients with advanced lung cancer. Clin Epigenetics 2015;7:119.
53. Schmidt B, Beyer J, Dietrich D, et al. Quantification of cell-free mSHOX2 Plasma DNA for therapy monitoring in advanced stage non-small cell (NSCLC) and small-cell lung cancer (SCLC) patients. PLoS One 2015;10:e0118195.
54. Salazar F, Molina MA, Sanchez-Ronco M, et al. Firstline therapy and methylation status of CHFR in serum influence outcome to chemotherapy versus EGFR tyrosine kinase inhibitors as second-line therapy in stage IV non-small-cell lung cancer patients. Lung Cancer 2011;72:84-91.
55. Juergens RA, Wrangle J, Vendetti FP, et al. Combination epigenetic therapy has efficacy in patients with refractory advanced non-small cell lung cancer. Cancer Discov 2011;1:598-607.
56. Lee TH, Montalvo L, Chrebtow V, et al. Quantitation of genomic DNA in plasma and serum samples: higher concentrations of genomic DNA found in serum than in plasma. Transfusion 2001;41:276-82.
57. Devonshire AS, Whale AS, Gutteridge A, et al. Towards standardisation of cell-free DNA measurement in plasma: controls for extraction efficiency, fragment size bias and quantification. Anal Bioanal Chem 2014;406:6499-512.
58. Mauger F, Dulary C, Daviaud C, et al. Comprehensive evaluation of methods to isolate, quantify, and characterize circulating cell-free DNA from small volumes of plasma. Anal Bioanal Chem 2015;407:6873-8.
59. Page K, Guttery DS, Zahra N, et al. Influence of plasma processing on recovery and analysis of circulating nucleic acids. PLoS One 2013;8:e77963.
60. Hernández HG, Tse MY, Pang SC, et al. Optimizing methodologies for PCR-based DNA methylation analysis. Biotechniques 2013;55:181-97.
61. Holmes EE, Jung M, Meller S, et al. Performance evaluation of kits for bisulfite-conversion of DNA from tissues, cell lines, FFPE tissues, aspirates, lavages, effusions, plasma, serum, and urine. PLoS One 2014;9:e93933.
62. Hayatsu H, Shiragami M. Reaction of bisulfite with the 5-hydroxymethyl group in pyrimidines and in phage DNAs. Biochemistry 1979;18:632-7.
63. Genereux DP, Johnson WC, Burden AF, et al. Errors in the bisulfite conversion of DNA: modulating inappropriate-and failed-conversion frequencies. Nucleic Acids Res 2008;36:e150.
64. Wielscher M, Vierlinger K, Kegler U, et al. Diagnostic Performance of Plasma DNA Methylation Profiles in Lung Cancer, Pulmonary Fibrosis and COPD. EBioMedicine 2015;2:929-36.
65. Ellinger J, Bastian PJ, Haan KI, et al. Noncancerous PTGS2 DNA fragments of apoptotic origin in sera of prostate cancer patients qualify as diagnostic and prognostic indicators. Int J Cancer 2008;122:138-43.
66. Hauser S, Zahalka T, Fechner G, et al. Serum DNA hypermethylation in patients with kidney cancer: results of a prospective study. Anticancer Res 2013;33:4651-6.
67. Lan X, Adams C, Landers M, et al. High resolution detection and analysis of CpG dinucleotides methylation using MBD-Seq technology. PLoS One 2011;6:e22226.
68. Nair SS, Coolen MW, Stirzaker C, et al. Comparison of methyl-DNA immunoprecipitation (MeDIP) and methyl-CpG binding domain (MBD) protein capture for genomewide DNA methylation analysis reveal CpG sequence coverage bias. Epigenetics 2011;6:34-44.
69. Kurdyukov S, Bullock M. DNA Methylation Analysis: Choosing the Right Method. Biology (Basel) 2016;5. pii: E3.
70. Huang YW, Huang TH, Wang LS. Profiling DNA methylomes from microarray to genome-scale sequencing. Technol Cancer Res Treat 2010;9:139-47.
71. Zhai R, Zhao Y, Su L, et al. Genome-wide DNA methylation profiling of cell-free serum DNA in esophageal adenocarcinoma and Barrett esophagus. Neoplasia 2012;14:29-33.
72. Chan KC, Jiang P, Chan CW, et al. Noninvasive detection of cancer-associated genome-wide hypomethylation and copy number aberrations by plasma DNA bisulfite sequencing. Proc Natl Acad Sci U S A 2013;110:18761-8.
73. Lun FM, Chiu RW, Sun K, et al. Noninvasive prenatal methylomic analysis by genomewide bisulfite sequencing of maternal plasma DNA. Clin Chem 2013;59:1583-94.
74. Legendre C, Gooden GC, Johnson K, et al. Wholegenome bisulfite sequencing of cell-free DNA identifies signature associated with metastatic breast cancer. Clin Epigenetics 2015;7:100.
75. Delaney C, Garg SK, Yung R. Analysis of DNA Methylation by Pyrosequencing. Methods Mol Biol 2015;1343:249-64.
76. Dupont JM, Tost J, Jammes H, et al. De novo quantitative bisulfite sequencing using the pyrosequencing technology. Anal Biochem 2004;333:119-27.
77. Ostrow KL, Hoque MO, Loyo M, et al. Molecular analysis of plasma DNA for the early detection of lung cancer by quantitative methylation-specific PCR. Clin Cancer Res 2010;16:3463-72.
78. Herman JG, Graff JR, Myöhänen S, et al. Methylationspecific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci U S A 1996;93:9821-6.
79. Eads CA, Danenberg KD, Kawakami K, et al. MethyLight: a high-throughput assay to measure DNA methylation. Nucleic Acids Res 2000;28:E32.
80. Weisenberger DJ, Trinh BN, Campan M, et al. DNA methylation analysis by digital bisulfite genomic sequencing and digital MethyLight. Nucleic Acids Res 2008;36:4689-98.
81. Yu M, Carter KT, Makar KW, et al. MethyLight droplet digital PCR for detection and absolute quantification of infrequently methylated alleles. Epigenetics 2015;10:803-9.
82. Li M, Chen WD, Papadopoulos N, et al. Sensitive digital quantification of DNA methylation in clinical samples. Nat Biotechnol 2009;27:858-63.
83. Day E, Dear PH, McCaughan F. Digital PCR strategies in the development and analysis of molecular biomarkers for personalized medicine. Methods 2013;59:101-7.
84. Clinical Laboratory Improvement Amendments (CLIA). Available online: http://wwwn.cdc.gov/clia/
85. Imaging and Biomarkers for Early Detection of Aggressive Cancer. Available online: http://grants.nih.gov/grants/guide/pa-files/PAR-16-089.html
86. Biomarker, Imaging and Quality of Life Studies Funding Program (BIQSFP). Available online: http://www.cancer.gov/about-nci/organization/ccct/funding/biqsfp
87. Epi proColon Approval Order. Available online: http://www.accessdata.fda.gov/cdrh_docs/pdf13/P130001A.pdf
88. Payne SR. From discovery to the clinic: the novel DNA methylation biomarker (m)SEPT9 for the detection of colorectal cancer in blood. Epigenomics 2010;2:575-85.
89. Characterization of Methylation Patterns in Lung Cancer. Available online: https://clinicaltrials.gov/ct2/show/NCT02373917
90. Biomarkers in Tissue and Blood Samples From Patients With Early-Stage Non-Small Cell Lung Cancer. Available online: https://clinicaltrials.gov/ct2/show/NCT01139944
91. Residual Hypermethylation in Early Stage Non-Small Cell Lung Cancer (NSCLC) As Part of Adjuvant Therapy and Preventive Strategy. Available online: https://clinicaltrials.gov/ct2/show/NCT01209520